BACKGROUND: The cardiac output (CO) response to exercise and other invasively derived hemodynamic variables has been variably described to provide better prognostication than peak V(O(2)) in patients with chronic heart failure. Using noninvasive measurements of CO during exercise, we compared the prognostic value of peak CO and cardiac power to peak V(O(2)) in chronic heart failure patients. METHOD AND RESULTS: One hundred seventy-one consecutive patients with chronic heart failure underwent symptom limited bicycle exercise with noninvasive estimation of CO using an inert gas rebreathing method. An accurate measure of peak CO was obtained in 148 patients (85% of patients; mean age, 53+/-14 years; 80% male; left ventricular ejection fraction, 24+/-12%; ischemic etiology, 34%). Peak cardiac power was derived from the product of the peak mean arterial blood pressure and CO divided by 451. End points consisted of death, urgent heart transplant, or left ventricular assist device implantation. Duration of follow-up averaged 337+/-252 days (median, 295 days). Univariate and multivariate analysis were performed. The variables analyzed included peak V(O(2)), peak CO, peak cardiac power, V(E)/V(CO(2)) slope, and V(O(2)) at anaerobic threshold. Event-free survival for the entire cohort was 83% with 5 deaths, 4 left ventricular assist device implants, and 16 urgent transplants. Peak V(O(2)) was 12.9+/-4.5 mL/kg per min, and peak cardiac power was 1.7+/-0.9 W. Peak V(O(2)), peak CO, peak cardiac power, V(E)/V(CO(2)) slope, and V(O(2)) at anaerobic threshold were predictive of outcome on univariate analysis. On multivariate analysis, peak cardiac power and peak CO were predictive of outcome with peak cardiac power being the most powerful independent predictor of outcome (P=0.01). CONCLUSIONS: Peak cardiac power, measured noninvasively, is an independent predictor of outcome that can enhance the prognostic power of peak V(O(2)) in the evaluation of patients with heart failure.
BACKGROUND: The cardiac output (CO) response to exercise and other invasively derived hemodynamic variables has been variably described to provide better prognostication than peak V(O(2)) in patients with chronic heart failure. Using noninvasive measurements of CO during exercise, we compared the prognostic value of peak CO and cardiac power to peak V(O(2)) in chronic heart failurepatients. METHOD AND RESULTS: One hundred seventy-one consecutive patients with chronic heart failure underwent symptom limited bicycle exercise with noninvasive estimation of CO using an inert gas rebreathing method. An accurate measure of peak CO was obtained in 148 patients (85% of patients; mean age, 53+/-14 years; 80% male; left ventricular ejection fraction, 24+/-12%; ischemic etiology, 34%). Peak cardiac power was derived from the product of the peak mean arterial blood pressure and CO divided by 451. End points consisted of death, urgent heart transplant, or left ventricular assist device implantation. Duration of follow-up averaged 337+/-252 days (median, 295 days). Univariate and multivariate analysis were performed. The variables analyzed included peak V(O(2)), peak CO, peak cardiac power, V(E)/V(CO(2)) slope, and V(O(2)) at anaerobic threshold. Event-free survival for the entire cohort was 83% with 5 deaths, 4 left ventricular assist device implants, and 16 urgent transplants. Peak V(O(2)) was 12.9+/-4.5 mL/kg per min, and peak cardiac power was 1.7+/-0.9 W. Peak V(O(2)), peak CO, peak cardiac power, V(E)/V(CO(2)) slope, and V(O(2)) at anaerobic threshold were predictive of outcome on univariate analysis. On multivariate analysis, peak cardiac power and peak CO were predictive of outcome with peak cardiac power being the most powerful independent predictor of outcome (P=0.01). CONCLUSIONS: Peak cardiac power, measured noninvasively, is an independent predictor of outcome that can enhance the prognostic power of peak V(O(2)) in the evaluation of patients with heart failure.
Authors: Erik H Van Iterson; Eric M Snyder; Michael J Joyner; Bruce D Johnson; Thomas P Olson Journal: Int J Cardiol Date: 2015-08-14 Impact factor: 4.164
Authors: Hannah Rosenblum; Stephen Helmke; Paula Williams; Sergio Teruya; Margaret Jones; Daniel Burkhoff; Donna Mancini; Mathew S Maurer Journal: Congest Heart Fail Date: 2010-10-19
Authors: Frederik Trinkmann; Manuel Berger; Ursula Hoffmann; Martin Borggrefe; Jens J Kaden; Joachim Saur Journal: Clin Res Cardiol Date: 2011-07-01 Impact factor: 5.460
Authors: Justin L Grodin; Wilfried Mullens; Matthias Dupont; Yuping Wu; David O Taylor; Randall C Starling; W H Wilson Tang Journal: Eur J Heart Fail Date: 2015-04-28 Impact factor: 15.534
Authors: Marc A Sintek; Mark Gdowski; Brian R Lindman; Michael Nassif; Kory J Lavine; Eric Novak; Richard G Bach; Scott C Silvestry; Douglas L Mann; Susan M Joseph Journal: J Card Fail Date: 2015-07-09 Impact factor: 5.712
Authors: Steven Hsu; Swetha Kambhampati; Christopher M Sciortino; Stuart D Russell; Steven P Schulman Journal: Am Heart J Date: 2017-12-13 Impact factor: 4.749
Authors: R E Perkins; K G Hollingsworth; C Eggett; G A MacGowan; M G D Bates; M I Trenell; D G Jakovljevic Journal: Br J Anaesth Date: 2016-07 Impact factor: 9.166